DSG3分子於頭頸癌之臨床應用-預測癌症惡性程度及作為分子應用標的之方法與專一性抑制DSG3表現之RNA干擾序列運用方法

Translated title of the contribution: Clinical application of DSG3 molecule in head and neck cancers for predicting the degree of cancer malignancy, using as method of molecular application targets, and RNA interference sequence application method of specific inhibition of DSG3 expression

Joseph Tung-Chieh Chang (Inventor), Yin-Ju Chen (Inventor), Ann-Joy Cheng (Inventor)

Research output: Patent

Abstract

The present invention relates to a clinical application of DSG3 molecule in head and neck cancers for predicting degree of cancer malignancy, using as method of molecular application targets, and RNA interference sequence application method of specific inhibition of DSG3 expression, especially to prove that the highly expressed DSG3 gene relates to the size, depth, and metastasis of tumor by comparative analysis of highly expressed DSG3 in tumor tissue and clinical feature of cancer cells. Thus, the highly expressed gene may be used as clinical application, estimation of the degree of tumor malignancy, or application of molecular targets for head and neck cancers. Furthermore, the present invention is aiming at the DSG3 molecule in the cells to design a RNA interference sequence specific to mRNA of DSG3 to effectively inhibit the expression of DSG3 protein, the growth, invasion, and metastasis of the cancer cells.
Translated title of the contributionClinical application of DSG3 molecule in head and neck cancers for predicting the degree of cancer malignancy, using as method of molecular application targets, and RNA interference sequence application method of specific inhibition of DSG3 expression
Original languageChinese (Traditional)
IPCA61K 48/00(2006.01); C12N 15/11(2006.01)
StatePublished - 01 04 2007

Bibliographical note

公開公告號: 2.00711659E8
Announcement ID: 2.00711659E8

Fingerprint

Dive into the research topics of 'Clinical application of DSG3 molecule in head and neck cancers for predicting the degree of cancer malignancy, using as method of molecular application targets, and RNA interference sequence application method of specific inhibition of DSG3 expression'. Together they form a unique fingerprint.

Cite this